Haase, Christiane L.

LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals

Haase, C. L., Tybjærg-Hansen, A., Ali Qayyum, A., Schou, J., Nordestgaard, B. G., & Frikke-Schmidt, R. (2012) · The Journal of Clinical Endocrinology & Metabolism

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 282

Weight loss and risk reduction of obesity-related outcomes in 0·5 million people: evidence from a UK primary care database

Haase, C. L., Lopes, S., Olsen, A. H., Satylganova, A., Schnecke, V., & McEwan, P. (2021) · International Journal of Obesity

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 199

Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease

Haase, C. L., Tybjærg-Hansen, A., Grande, P., & Frikke-Schmidt, R. (2010) · The Journal of Clinical Endocrinology & Metabolism

Genetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Cited by 104

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada

Wharton, S., Liu, A., Pakseresht, A., Nørtoft, E., Haase, C. L., Mancini, J., Power, G. S., Vanderlelie, S., & Christensen, R. A. G. (2019) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 77

Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 metformin initiators

Svensson, E., Baggesen, L. M., Johnsen, S. P., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Thomsen, R. W. (2017) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 77

Persistence of newer anti-obesity medications in a real-world setting

Ganguly, R., Tian, Y., Kong, S. X., Hersloev, M., Hobbs, T., Smolarz, B. G., Ramasamy, A., Haase, C. L., & Weng, W. (2018) · Diabetes Research and Clinical Practice

Pharmacology and Obesity TreatmentMedication Adherence and Compliance

Cited by 68

Body mass index and risk of obesity‐related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database

Haase, C. L., Eriksen, K. T., Lopes, S., Satylganova, A., Schnecke, V., & McEwan, P. (2021) · Obesity Science & Practice

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 57

Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland

Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U. (2021) · Obesity Facts

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 41

Population-Based Resequencing of APOA1 in 10,330 Individuals: Spectrum of Genetic Variation, Phenotype, and Comparison with Extreme Phenotype Approach

Haase, C. L., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · PLoS Genetics

Genetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Cited by 37

Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes

Thomsen, R. W., Baggesen, L. M., Søgaard, M., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Johnsen, S. P. (2015) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 32

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

Wharton, S., Haase, C. L., Kamran, E., Liu, A., Mancini, J., Neish, D., Pakseresht, A., Power, G. S., & Christensen, R. A. G. (2020) · Obesity Science & Practice

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 26